SCHEMBL6062487

SCHEMBL6062487

CSCc1cc(C(F)(F)F)ccc1N(C(C)=O)C(C)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ EPHX1 P07099 2/20 0.35
▸ POLQ O75417 3/20 0.35
▸ PTGDR2 Q9Y5Y4 1/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ GFER P55789 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34
▸ CES2 O00748 2/20 0.34
▸ MAPT P10636 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ RXRA P19793 1/20 0.34
▸ NR1H2 P55055 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6063353 0.77 CES2 (0.41) CYP2C19ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL6063607 0.74 CYP1A2 (0.52) CYP3A4CYP2D6CYP2C19ALDH1A1CYP1A2
SCHEMBL21316578 0.72 IDO1 (0.53) CYP3A4CYP2D6
SCHEMBL5833100 0.71 CFTR (0.58) CYP2C19ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL3984430 0.70 SLC6A2 (0.40) CYP3A4CYP2D6EPHX1CYP2C19ALDH1A1
SCHEMBL11441775 0.67 SLC6A2 (0.43) CYP3A4CYP2C19ALDH1A1HPGDHSD17B10
SCHEMBL8131522 0.65 XPO1 (0.49) CYP3A4CYP2D6ALDH1A1
SCHEMBL16346493 0.65 AGBL2 (0.47) POLQALDH1A1HPGDKDM4EMAPT
SCHEMBL9807563 0.64 CRHBP (0.51) ALDH1A1HDAC6CES2MAPT
SCHEMBL10384398 0.64 ALDH1A1 (0.50) CYP2C19ALDH1A1HPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7145035-B2 Methods of ortho alkylation E. I. DU PONT DE NEMOURS AND COMPANY (US) 2006-12-05 — — US disclosed
US-20040082793-A1 Methods of ortho alkylation E. I. DU PONT DE NEMOURS AND COMPANY 2004-04-29 — — US disclosed
EP-1368310-A2 IMPROVED METHODS OF ORTHO ALKYLATION E. I. du Pont de Nemours and Company (US) 2003-12-10 — — EP disclosed
WO-2002072540-A2 IMPROVED METHODS OF ORTHO ALKYLATION E. I. DU PONT DE NEMOURS AND COMPANY (US) 2002-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082793-A1 Methods of ortho alkylation CBR1, AOC2, CBR3 CYP3A4 111/4885CYP2D6 105/4885EPHX1 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback